Vikram Malhi1, Nageshwar Budha2, Rucha Sane3, Jian Huang4, Bianca Liederer5, Raymond Meng6, Premal Patel7, Yuzhong Deng4, Andres Cervantes8, Josep Tabernero9, Luna Musib3. 1. Clinical Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA. malhi.vikram@gene.com. 2. Clinical Pharmacology, BeiGene, San Mateo, CA, USA. 3. Clinical Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA. 4. Safety Science, Genentech, Inc., South San Francisco, CA, USA. 5. Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USA. 6. Clinical Science, Genentech, Inc., South San Francisco, CA, USA. 7. eFFECTOR Therapeutics, Inc., San Diego, CA, USA. 8. INCLIVA, University of Valencia, Valencia, Spain. 9. Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain.
Abstract
PURPOSE: To examine the single- and multiple-dose pharmacokinetics (PK), CYP3A inhibition potential of ipatasertib, and effect of food on PK of ipatasertib in patients with refractory solid tumors and a dedicated food effect assessment in healthy subjects. METHODS: The Phase I dose-escalation study enrolled patients with solid tumors in a standard 3 + 3 design with a 1 week washout after the first dose, followed by once-daily dosing on a 3-week-on/1-week-off schedule. In the expansion cohort, the effect of ipatasertib on CYP3A substrate (midazolam) was assessed by examining the change in midazolam exposure when dosed in the absence and presence of steady-state ipatasertib at 600 mg. The effect of food on ipatasertib PK was studied with ipatasertib administered in fed or fasted state (6 patients from Phase I patient study and 18 healthy subjects from the dedicated food effect study). RESULTS: Ipatasertib was generally well tolerated at doses up to 600 mg given daily for 21 days. Ipatasertib showed rapid absorption (tmax, 0.5-3 h), was dose-proportional over a range of 200-800 mg, had a median half-life (range) of 45.0 h (27.8-66.9 h), and had approximately two-fold accumulation following once-daily dosing. Midazolam exposure (AUC0-∞) increased by 2.2-fold in the presence of ipatasertib. PK was comparable in subjects administered ipatasertib in a fed or fasted state. CONCLUSION: Ipatasertib exhibited rapid absorption and was dose-proportional over a broad dose range. Ipatasertib appeared to be a moderate CYP3A inhibitor when administered at 600 mg and could be administered with or without food in clinical studies. TRAIL REGISTRATION: NCT01090960 (registered March 23, 2010); NCT02536391 (registered August 31, 2015).
PURPOSE: To examine the single- and multiple-dose pharmacokinetics (PK), CYP3A inhibition potential of ipatasertib, and effect of food on PK of ipatasertib in patients with refractory solid tumors and a dedicated food effect assessment in healthy subjects. METHODS: The Phase I dose-escalation study enrolled patients with solid tumors in a standard 3 + 3 design with a 1 week washout after the first dose, followed by once-daily dosing on a 3-week-on/1-week-off schedule. In the expansion cohort, the effect of ipatasertib on CYP3A substrate (midazolam) was assessed by examining the change in midazolam exposure when dosed in the absence and presence of steady-state ipatasertib at 600 mg. The effect of food on ipatasertib PK was studied with ipatasertib administered in fed or fasted state (6 patients from Phase I patient study and 18 healthy subjects from the dedicated food effect study). RESULTS: Ipatasertib was generally well tolerated at doses up to 600 mg given daily for 21 days. Ipatasertib showed rapid absorption (tmax, 0.5-3 h), was dose-proportional over a range of 200-800 mg, had a median half-life (range) of 45.0 h (27.8-66.9 h), and had approximately two-fold accumulation following once-daily dosing. Midazolam exposure (AUC0-∞) increased by 2.2-fold in the presence of ipatasertib. PK was comparable in subjects administered ipatasertib in a fed or fasted state. CONCLUSION: Ipatasertib exhibited rapid absorption and was dose-proportional over a broad dose range. Ipatasertib appeared to be a moderate CYP3A inhibitor when administered at 600 mg and could be administered with or without food in clinical studies. TRAIL REGISTRATION: NCT01090960 (registered March 23, 2010); NCT02536391 (registered August 31, 2015).
Authors: James F Blake; Rui Xu; Josef R Bencsik; Dengming Xiao; Nicholas C Kallan; Stephen Schlachter; Ian S Mitchell; Keith L Spencer; Anna L Banka; Eli M Wallace; Susan L Gloor; Matthew Martinson; Richard D Woessner; Guy P A Vigers; Barbara J Brandhuber; Jun Liang; Brian S Safina; Jun Li; Birong Zhang; Christine Chabot; Steven Do; Leslie Lee; Jason Oeh; Deepak Sampath; Brian B Lee; Kui Lin; Bianca M Liederer; Nicholas J Skelton Journal: J Med Chem Date: 2012-09-18 Impact factor: 7.446
Authors: Johann S de Bono; Ugo De Giorgi; Daniel Nava Rodrigues; Christophe Massard; Sergio Bracarda; Albert Font; Jose Angel Arranz Arija; Kent C Shih; George Daniel Radavoi; Na Xu; Wai Y Chan; Han Ma; Steven Gendreau; Ruth Riisnaes; Premal H Patel; Daniel J Maslyar; Viorel Jinga Journal: Clin Cancer Res Date: 2018-07-23 Impact factor: 12.531
Authors: Jie Lin; Deepak Sampath; Michelle A Nannini; Brian B Lee; Michael Degtyarev; Jason Oeh; Heidi Savage; Zhengyu Guan; Rebecca Hong; Robert Kassees; Leslie B Lee; Tyler Risom; Stefan Gross; Bianca M Liederer; Hartmut Koeppen; Nicholas J Skelton; Jeffrey J Wallin; Marcia Belvin; Elizabeth Punnoose; Lori S Friedman; Kui Lin Journal: Clin Cancer Res Date: 2013-01-03 Impact factor: 12.531